Andrew Maxwell

Andrew Maxwell has a wealth of experience in medical technology. For 10 years, Mr Maxwell led the global growth of Global Kinetics Corporation (GKC) as managing director and chief executive. GKC commercialised a research project emanating from the Florey Institute of Neuroscience and Mental Health, and created a global company with a market-leading product for the remote measurement, and reporting of the movement disorder symptoms of Parkinson’s disease. GKC gained FDA clearance in the USA, Class 1 and Class 2a CE mark in Europe and TGA registration in Australia for its Parkinson’s KinetiGraph (PKG) and PKG Watch, a wearable medical device and a mobile health IT software system. GKC was the sponsor manufacture of product and via its own direct sales and marketing team, implemented the PKG in over 140 hospitals in 16 countries providing more than 65,000 people with Parkinson’s access to a clinical test that will make a meaningful difference to the management of their condition. Prior to GKC, as chief executive of ESCOR Private Equity (a Smorgon Family Company), Mr Maxwell established and managed a $40m investment fund focused on investing in the IT, Internet, Biotech, and Healthcare sectors in Australia, the USA and Europe. Mr Maxwell was also a member of the ESCOR Group Investment Coordination Committee, evaluating capital allocation and investments strategy for the ESCOR Group.
Bio last updated 03 Mar 2019

Article Timeline

Positions - Previous

PositionCompanyYearCompany's current rankWA staff
Non-Executive Director
2017 - 2019

Directors Interests

CompanyDateTransaction typeNumber of sharesPrice per shareTransaction valueNature of change
Medibio06 Nov 2018Bought216,002$0.04$9,434On-market trade
Medibio18 Jun 2018Issued559,556OtherIssue of securities
Medibio02 Aug 2017Bought26,000$0.38$9,880On-market trade
Powered by Morningstar ®

Share Transactions

$9k Bought
$0 Issued
$10k Bought
Total value as at the date of the transaction
Powered by Morningstar ®